The Effects of Psilocybin on Social Connectedness (Phase 1, Yale University, n=51, recruiting) — The study is a randomized, double-blind, placebo-controlled, expectancy-controlled, mechanistic trial.…
Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self (Observational, University of Zurich, n=140, completed) — The aim of the study is to identify neural signatures, behavioral and phenomenological expressions of self-related processes including: sense of agency, semantic distinction between self and other, selflessness (altruism), social agency, embodied self (interoception), perceptual functioning of dissolved self including hallucinations and crossmodal processing, and finally the mystical type dissolution of the self.
MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial (Phase 2, University of Calgary, n=60, recruiting) — This pilot clinical trial will study psilocybin-assisted therapy for adults with advanced cancer who are experiencing demoralization, existential distress, or related psychological concerns.…
Healing in Community: Reflections on Racial Trauma and Plant Medicine in Oaxaca (News) — A retreat was organized in Oaxaca, Mexico, for racialized psychotherapists to explore whether psilocybin mushrooms could support healing from racial trauma when approached with cultural responsibility. The event aimed to create space for practitioners to reflect on their experiences and receive care, while respecting the cultural context of plant medicine practices.
Weekly Psychedelic Policy Briefing: August 14, 2026 (Phase 3, U.S. Department of Veterans Affairs (VA), recruiting) — The U.S. Department of Veterans Affairs (VA) has launched PIVOT, a five-site clinical trial evaluating the therapeutic use of psilocybin (COMP360) for veterans with treatment-resistant depression. The trial aims to establish safety parameters and dosing protocols, potentially influencing future insurance reimbursement for psilocybin therapy.
A real-world study of Oregon's nonmedical psilocybin program shows promise (Observational, Oregon Health & Science University, n=350) — A study of nearly 350 people who took psilocybin in Oregon's regulated program found that most participants described their experience as beneficial, with over half ranking it among the most meaningful experiences of their lives. The data also suggests the program was overall quite safe, with a very small number reporting serious adverse reactions.
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA (Regulatory, Multidisciplinary Association for Psychedelic Studies (MAPS), approved) — MAPS responded to a report that Resilient Pharmaceuticals resubmitted its new drug application (NDA) for MDMA-assisted therapy for PTSD to the FDA. This follows a Complete Response Letter issued in August 2024, which recommended additional research. The new guidance from the FDA addresses areas central to the previous recommendations.
Complex regional pain syndrome and amputation. (Meta-analysis) — Complex regional pain syndrome (CRPS) is a debilitating poorly understood condition with unpredictable course and heterogeneous therapeutic responses. Early, coordinated multidisciplinary management, including psychological and psychiatric support, is essential.…
Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression (Observational, Yale University, n=28, completed) — The goals of this study are: 1) to investigate the efficacy of combining ketamine with intensive cognitive behavioral therapy (CBT) to sustain the antidepressant effects of ketamine; and 2) to determine ketamine's delayed effects on learning and memory, and to explore the relationship between any ketamine-induced changes in learning and memory and duration of antidepressant efficacy, with and without CBT augmentation.…
Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression (Observational, Peking University First Hospital, n=364, completed) — Prenatal depression is an important risk factor of postpartum depression. Low-dose ketamine has been used for depression treatment. As a stereoisomer of ketamine, s-ketamine has similar effects to ketamine in anti-depression.…
Intranasal (NAS) Ketamine for Cancer Pain (Phase 1, Emory University, n=10, completed) — The main purpose of this study is to determine the safety, feasibility, and utility of intranasal (NAS) ketamine in persistent uncontrolled cancer related pain.…
Ketamine + Cognitive Training for Suicidality in the Medical Setting (Observational, Rebecca Price, n=200, active) — This project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting.…
The Role of Ketamine and Dexmedetomidine in Opioid-Sparing Analgesia (Observational, Fayoum University Hospital, n=90, completed) — Optimal multimodal opioid-sparing analgesic technique is considered as one of the most important Enhanced recovery pathways (ERPs) or enhanced recovery after surgery (ERAS) interventions that mitigate the undesirable effects of surgical stress response.…
Is Ketamine for Depression Moving Too Fast on Weak Data? (Phase 3, Trinity College Dublin, n=62) — A randomized controlled trial at Trinity College Dublin found that adding ketamine to usual inpatient care offered no additional benefit compared to a psychoactive placebo for depression symptoms. Meta-analyses suggest short-term antidepressant effects, but concerns remain about study limitations and safety.
Ibogaine
University of Miami’s Gift (Regulatory, University of Miami, approved) — MAPS welcomed the University of Miami's gift of its 1994 ibogaine Investigational New Drug (IND) application to the federal government. MAPS provided initial funding for this research in the 1990s and has since published its own Ibogaine Investigator's Brochure to consolidate decades of data.
ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1 (Observational, Salma Health, Inc., n=5000, recruiting) — This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings.…
Queering Psychedelics 2026 (News, Chacruna) — This event celebrates Chacruna's 10th anniversary and the book 'Queering Psychedelics' with a community conversation focusing on queer voices, Indigenous reciprocity, and inclusivity in the psychedelic future. It highlights the intersection of psychedelics with social justice, gender, and sexuality, featuring speakers like Bia Labate, Clancy Cavnar, and Paulina Valamiel.
Conspirituality: Seeking Hidden Truths in the Post-Truth Era (News, University of Humanistic Studies) — This article discusses the intersection of spirituality and conspiracy thinking, exploring how psychedelic and contemplative practices can influence the perception of truth and the potential for self-sealing beliefs. It examines epistemic discernment and critiques conspirituality without replicating its logic.
FDA moves to fast-track review of psilocybin and methylone for mental health (Regulatory, FDA, approved) — The FDA issued national priority vouchers to three companies studying psychedelic-based medicines: psilocybin for treatment-resistant depression and major depressive disorder, and methylone for PTSD. These vouchers aim to fast-track the review process for these drugs.